Physician profile
Christopher E Larson
NPI 1831112747
$2,509.67
in general payments reported to CMS, 2019-2025
32 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $336 · 2021: $401 · 2022: $263 · 2023: $231 · 2024: $115 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $408.11 | 2019-2023 | Erleada |
| Astellas Pharma US INC | $390.74 | 2019-2022 | |
| Abbvie INC. | $237.59 | 2019-2025 | |
| Pfizer INC. | $169.47 | 2019-2023 | |
| Neotract INC. | $149.84 | 2019 | |
| Calyxo, INC. | $145.71 | 2025 | Cvac Aspiration System |
| Teleflex LLC | $139.35 | 2022-2025 | Urolift, Barrigel |
| 180 Medical, INC. | $71.94 | 2019-2023 | Gentlecath Glide |
| Procept Biorobotics Corporation | $70.34 | 2022-2025 | |
| Coloplast Corp | $64.48 | 2021-2022 | |
| Medtronic USA, INC. | $64.47 | 2020 | |
| Amgen INC. | $61.97 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $46.88 | 2022 | |
| Merck Sharp & Dohme LLC | $44.84 | 2020-2021 | |
| Medtronic, INC. | $39.25 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.26 | 2019-2020 | |
| Allergan, INC. | $34.49 | 2019-2020 | |
| Davol INC. | $34.37 | 2020 | |
| Travere Therapeutics, INC. | $28.83 | 2019-2020 | |
| Karl Storz Endoscopy-America | $28.03 | 2019 | |
| Convatec INC. | $27.98 | 2023 | |
| Myovant Sciences INC. | $27.18 | 2021 | |
| Tolmar, INC. | $27.08 | 2024 | |
| Olympus America INC. | $18.59 | 2023 | Itind System |
| Kowa Pharmaceuticals America, INC. | $18.30 | 2023 | Seglentis |
| Rochester Medical Corporation | $17.25 | 2020 | |
| Urogen Pharma, INC. | $17.23 | 2023 | Jelmyto |
| Blue Earth Diagnostics | $15.26 | 2021 | |
| Srs Medical Systems, INC. | $13.26 | 2023 | Urocuff |
| Dendreon Pharmaceuticals LLC | $12.62 | 2019 | |
| Isoray, INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.